| Heart disease and stroke statistics—2017 update: a report from the American Heart Association EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ... circulation 135 (10), e146-e603, 2017 | 17320 | 2017 |
| Evolocumab and clinical outcomes in patients with cardiovascular disease MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, ... New England journal of medicine 376 (18), 1713-1722, 2017 | 5697 | 2017 |
| Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian … PS Sever, B Dahlöf, NR Poulter, H Wedel, G Beevers, M Caulfield, ... The Lancet 361 (9364), 1149-1158, 2003 | 5595 | 2003 |
| Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the … B Dahlöf, PS Sever, NR Poulter, H Wedel, DG Beevers, M Caulfield, ... The Lancet 366 (9489), 895-906, 2005 | 4740 | 2005 |
| Genetic studies of body mass index yield new insights for obesity biology AE Locke, B Kahali, SI Berndt, AE Justice, TH Pers, FR Day, C Powell, ... Nature 518 (7538), 197-206, 2015 | 4707 | 2015 |
| Treatment of hypertension in patients 80 years of age or older NS Beckett, R Peters, AE Fletcher, JA Staessen, L Liu, D Dumitrascu, ... New England Journal of Medicine 358 (18), 1887-1898, 2008 | 4634 | 2008 |
| Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials CT Trialists The Lancet 376 (9753), 1670-1681, 2010 | 4282* | 2010 |
| Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials F Turnbull, B Neal, C Algert, J Chalmers, M Woodward, S MacMahon, ... Lancet 362 (9395), 1527-1535, 2003 | 3120 | 2003 |
| Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension PM Rothwell, SC Howard, E Dolan, E O'Brien, JE Dobson, B Dahlöf, ... The Lancet 375 (9718), 895-905, 2010 | 2455 | 2010 |
| Defining the role of common variation in the genomic and biological architecture of adult human height AR Wood, T Esko, J Yang, S Vedantam, TH Pers, S Gustafsson, AY Chu, ... Nature genetics 46 (11), 1173-1186, 2014 | 2087 | 2014 |
| Interpretation of the evidence for the efficacy and safety of statin therapy R Collins, C Reith, J Emberson, J Armitage, C Baigent, L Blackwell, ... The Lancet 388 (10059), 2532-2561, 2016 | 1964 | 2016 |
| Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV B Williams, NR Poulter, MJ Brown, M Davis, GT McInnes, JF Potter, ... Journal of human hypertension 18 (3), 139-185, 2004 | 1371 | 2004 |
| Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits E Evangelou, HR Warren, D Mosen-Ansorena, B Mifsud, R Pazoki, H Gao, ... Nature genetics 50 (10), 1412-1425, 2018 | 1202 | 2018 |
| Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial B Williams, TM MacDonald, S Morant, DJ Webb, P Sever, G McInnes, ... The Lancet 386 (10008), 2059-2068, 2015 | 1129 | 2015 |
| British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary B Williams, NR Poulter, MJ Brown, M Davis, GT McInnes, JF Potter, ... Bmj 328 (7440), 634-640, 2004 | 1027 | 2004 |
| Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke PM Rothwell, SC Howard, E Dolan, E O'Brien, JE Dobson, B Dahlöf, ... The Lancet Neurology 9 (5), 469-480, 2010 | 906 | 2010 |
| Effect of spironolactone on blood pressure in subjects with resistant hypertension N Chapman, J Dobson, S Wilson, B Dahlof, PS Sever, H Wedel, ... hypertension 49 (4), 839-845, 2007 | 823 | 2007 |
| HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials DI Swerdlow, D Preiss, KB Kuchenbaecker, MV Holmes, JEL Engmann, ... The Lancet 385 (9965), 351-361, 2015 | 743 | 2015 |
| Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials JL Mega, NO Stitziel, JG Smith, DI Chasman, MJ Caulfield, JJ Devlin, ... The Lancet 385 (9984), 2264-2271, 2015 | 727 | 2015 |
| Lipoprotein (a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial ML O’Donoghue, S Fazio, RP Giugliano, ESG Stroes, E Kanevsky, ... Circulation 139 (12), 1483-1492, 2019 | 714 | 2019 |
